FIELD: pharmaceuticals.
SUBSTANCE: herein the compounds, compositions, and methods useful for inhibiting a protein tyrosine phosphatase, such as a non-receptor type 2 protein tyrosine phosphatase (PTPN2) and/or a non-receptor type 2 protein tyrosine phosphatase are provided. The invention relates to a compound which is
and its pharmaceutically acceptable salt.
EFFECT: new compound has been obtained that is suitable for inhibiting protein tyrosine phosphatase, for example, non-receptor type 2 protein tyrosine phosphatase (PTPN2) and/or non-receptor type 1 protein tyrosine phosphatase (PTPN1), and for the treatment of associated diseases, disorders and conditions that respond favorably to for treatment with PTPN1 or PTPN2 inhibitors, such as cancer or metabolic disorders.
4 cl, 227 ex, 6 tbl
Title | Year | Author | Number |
---|---|---|---|
MODULATORS OF INTEGRATED STRESS SIGNALING PATH | 2017 |
|
RU2769327C2 |
NOVEL COMPOUNDS | 2001 |
|
RU2419608C2 |
ANTI-HER2 ANTIBODY DRUG CONJUGATE | 2015 |
|
RU2794183C2 |
ANTI-HER2 ANTIBODY-DRUG CONJUGATE | 2015 |
|
RU2683780C2 |
INHIBITORS OF HIV REPLICATION | 2011 |
|
RU2564445C2 |
DERIVATIVES OF PIPERIDINE, METHODS FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2001 |
|
RU2298550C2 |
INHIBITORS OF METALLOPROTEINASES, THEIR USING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2288228C2 |
1,3-BENZODIOXOLE DERIVATIVE | 2015 |
|
RU2679131C2 |
SULTAM-BASED COMPOUND AND METHOD OF USE THEREOF | 2017 |
|
RU2741915C2 |
PHENICOL ANTIBACTERIAL AGENTS | 2013 |
|
RU2593204C2 |
Authors
Dates
2023-07-05—Published
2019-06-21—Filed